GEN Exclusives

More »

GEN News Highlights

More »
Oct 26, 2006

AstraZeneca’s Stroke Drug Trial Failure Precipitates Stock Tumble

  • Astrazeneca reports that it has decided to discontinue development of NXY-059 in acute ischemic stroke based on negative results from its Phase III trial.

    “NXY-059’s lack of efficacy in the SAINT trial II is disappointing for stroke patients in view of the significant unmet medical need,” reports Tomas Odergren, vp, global product director for NXY-059.

    The SAINT II (Stroke Acute Ischemic NXY-059 Treatment) trial showed that NXY-059 did not meet its primary outcome of a statistically significant reduction in stroke-related disability compared to placebo. Subgroup analyses, including time to treatment, did not demonstrate a treatment benefit.

    In addition, NXY-059 did not cause a statistically significant improvement in neurological status versus placebo on the NIH Stroke Scale; there was no evidence of NXY-059 lowering the incidence of symptomatic intracranial haemorrhage when administered with rt-PA; and mortality, the incidence, and profile of adverse events in patients receiving NXY-059 were similar to placebo.

    The company’s stock declined more than 7% on the London, Stockholm, and New York exchange.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?